04624nam 2200589Ia 450 991045220250332120200520144314.01-60876-707-8(CKB)2550000001041297(EBL)3018377(SSID)ssj0000835562(PQKBManifestationID)12354374(PQKBTitleCode)TC0000835562(PQKBWorkID)10989961(PQKB)11461328(MiAaPQ)EBC3018377(Au-PeEL)EBL3018377(CaPaEBR)ebr10660238(OCoLC)844348818(EXLCZ)99255000000104129720091021d2009 uy 0engur|n|---|||||txtccrImmunosuppression[electronic resource] new research /Charles B. Taylor, editorNew York Nova Science Pub. Inc.20091 online resource (320 p.)Description based upon print version of record.1-60692-102-9 Includes bibliographical references and index.""Immunosuppression: New Research""; ""Contents""; ""Preface""; ""Is There a Future for Costimulation Blockade as a Regulatory T-cell Inducing Therapy?""; ""Abstract""; ""Introduction""; ""Costimulation Blockade""; ""Regulatory T-Cells""; ""Conclusion""; ""References""; ""Strategies for T Cell Depletion to Prevent Graft versus Host Disease""; ""Abstract""; ""Introduction""; ""Pharmacological Intervention""; ""T Cell Depletion - An Effective Non-PharmacologicImmunosuppression""; ""Pre �Clinical Models and Early Clinical Studies""; ""Strategies of T Cell Depletion""""Merits and Problems with TCD""""Haploidentical Transplantation""; ""Strategies to Improve Outcome of Patients with TCell Depletion""; ""Conclusions""; ""References""; ""Leucocyte Intracellular Cytokines in Lung Transplant Patients- A More Physiological Indicator of Immunosuppression than Plasma Drug Levels""; ""Abstract""; ""Introduction""; ""Acute and Chronic Transplant Rejection""; ""Immunosuppression""; ""Conclusion""; ""References""; ""Indications and Management of m-TOR Inhibitors after Liver Transplantation""; ""Abstract""; ""Introduction""; ""Objectives""; ""Material and Methods""""Results""""Discussion""; ""References""; ""Evolution of Immunosuppression in Liver Transplantation""; ""Abstract""; ""Abbreviations""; ""Introduction""; ""Evolution of Immunosuppression""; ""Recent Advances in ImmunosuppressionFollowing Liver Transplantation""; ""Conclusion""; ""References""; ""The Role of Pharmacogenomics in Tailoring Immunosuppressive Therapy for Liver Transplant Recipients""; ""Abstract""; ""Introduction""; ""Current Immunosuppressive Drugs""; ""Pharmacogenomics and Drug Metabolism""; ""Genetic Polymorphism and Immunosuppressive Drugs""""Limitations of Clinical application of Pharmacogenomics""""Conclusion""; ""References""; ""Immunosuppression Caused by Photochemo- and Photodynamic Therapy: Focus on Photosensitizer Photoproducts""; ""Abstract""; ""Introduction""; ""Suppression of Delayed Type Hypersensitivity (DTH) Reaction by Products of Photosensitizer Photooxidation""; ""Suppression of Contact Hypersensitivity (CHS) by PUVA-Treatment and by Photosensitizer Photoproducts""; ""POP Therapy Is a New Patient-Friendly Photochemotherapy That Requires No UV-A Irradiation of Skin or Blood""; ""Conclusion""; ""References""""Sunlight Induced Immunosuppression: A Role for Inflammatory Mediators in the Induction of Suppressor Cells""""Abstract""; ""Introduction""; ""Immunosuppression Only Requires Exposure toLow Doses of UV Radiation""; ""Sunlight Is Immunosuppressive""; ""UV-Induced Regulatory Cells""; ""Factors Involved in the Activationof UV-Regulatory Cells""; ""Dendritic Cells as Mediators of Regulatory T Cell Activation""; ""Mast Cells and the Activation of RegulatoryPopulations in Secondary Lymphoid Tissues""; ""Regulatory B Cells as Facilitatorsof UV-Immunosuppression""; ""Conclusion""; ""References""""Immunosuppressive Therapy in Adult to Adult Living-Related Liver Transplantation""ImmunosuppressionImmunosuppressive agentsElectronic books.Immunosuppression.Immunosuppressive agents.615.37Taylor Charles B971007MiAaPQMiAaPQMiAaPQBOOK9910452202503321Immunosuppression2206961UNINA